Structural Formula (Lev1d 0003 01)
Chemical structure of levetiracetam showing a pyrrolidone ring attached to an ethyl group and a carbamoyl group.*
Levetiracetam Injection, Solution
Product Images NDC 63323-400
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 63323-400). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Fresenius Kabi Usa, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Lev1d 0003 02)
A bar chart showing the percentage of patients across three groups: Placebo (7.4%), Levetiracetam 1,000 mg/day (37.1%), and Levetiracetam 3,000 mg/day (39.6%). The chart presents patient response rates linked to different treatments of Levetiracetam compared to placebo.*
Figure 2 (Lev1d 0003 03)
A bar graph displaying the percentage of patients in three groups: Placebo (6.3%), Levetiracetam 1,000 mg/day (20.8%), and Levetiracetam 2,000 mg/day (35.2%). The patient counts for each group are shown below the bars.*
Figure 3 (Lev1d 0003 04)
A bar chart comparing the percentage of patients between two groups: Placebo (104 patients) at 14.4% and Levetiracetam 3,000 mg/day (180 patients) at 39.4%. The y-axis represents the percentage of patients, and the two groups are displayed on the x-axis, highlighting a higher percentage in the Levetiracetam group.*
Figure 4 (Lev1d 0003 05)
A bar chart comparing the percentage of patients for placebo versus Levetiracetam, showing 19.6% for placebo and 44.6% for Levetiracetam. The x-axis categorizes the groups (Placebo and Levetiracetam) with sample sizes noted, and the y-axis represents the percentage of patients from 0% to 45%.*
Figure 5 (Lev1d 0003 06)
A bar chart comparing percentages of patients between two groups: Placebo (N=51) at 19.6% and Levetiracetam (N=58) at 43.1%. The y-axis represents the percentage of patients from 0% to 45%. A star symbol is shown above the Levetiracetam bar.*
Figure 6 (Lev1d 0003 07)
A bar chart comparing the percentage of patients between two groups: Placebo (N=84) at 45.2% and Levetiracetam (N=79) at 72.2%. The y-axis represents the percentage of patients, ranging from 0% to 100%, illustrating a higher percentage response in the Levetiracetam group.*
Premierprorx Logo (Lev1d 0003 08)
Package Label (PRINCIPAL DISPLAY – Levetiracetam 5 mL Tray Label)
Levetiracetam Injection, USP 500 mg per 5 mL (100 mg per mL) vial label from Fresenius Kabi USA, LLC. The label states it is for intravenous use only and must be diluted, with each vial containing 500 mg levetiracetam along with sodium acetate, sodium chloride, and glacial acetic acid for pH adjustment. Package size is 10 single dose vials of 5 mL each.*
Package Label (PRINCIPAL DISPLAY – Levetiracetam 5 mL Tray Label)
Levetiracetam Injection, USP label showing 500 mg per 5 mL (100 mg per mL) strength. The single-dose vial is for intravenous use only and must be diluted. The label includes storage conditions at 20° to 25°C and specifies it is manufactured by Fresenius Kabi USA, LLC. The NDC code 63323-400-41 is displayed with dosage and ingredient details.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
